Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Treatment profiles

From: Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

Tumor response n (%)
 CR 1 (2.8)
 PR 19 (52.8)
 SD 13 (36.1)
 PD 0 (0)
 Not evaluated 3 (8.3)
 Response rate (CR + PR) 20 (55.6)
 Disease control rate (CR + PR + SD) 33 (91.7)
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease
Back to article page